Searchable abstracts of presentations at key conferences in endocrinology

ea0063p263 | Pituitary and Neuroendocrinology 1 | ECE2019

Baseline characteristics of adult patients with growth hormone deficiency (GHD) enrolled in NordiNet® International Outcome Study (IOS): are there variations between countries?

Weber Matthias M , Pietropoli Alberto , Hoybye Charlotte

Czech Republic background: NordiNet® IOS (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin. From 23 countries, 2,321 adults with GHD were included; 971, GH-naïve at baseline, were included in the effectiveness analysis set (EAS). Baseline characteristics in the six largest contributing countries were evaluated.Methods: Patient information was ente...

ea0066p72 | Pituitary | BSPED2019

Real-world safety data in children with Noonan syndrome treated with growth hormone: results from NordiNet®IOS and the Answer®Program

Juliusson Petur , Dahlgren Jovanna , Abuzzahab Jennifer , Blair Jo , Pietropoli Alberto , Romano Alicia

Objective: To describe real-world safety data on growth hormone therapy (GHT) in paediatric patients with Noonan syndrome (NS) who were enrolled in NordiNet® IOS and the ANSWER®Program.Introduction: Patients with NS have a high prevalence of cardiac defects and an increased risk for leukaemia and certain malignancies compared to the general population. Current safety data do not indicate an association of GHT with worsenin...

ea0070aep749 | Pituitary and Neuroendocrinology | ECE2020

Pregnancy outcomes in women receiving growth hormone therapy enrolled in NordiNet international outcome study (IOS) and American Norditropin Studies: Web Enabled Research (ANSWER Program)

Biller Beverly , Höybye Charlotte , Camilla Birkegård Anna , Pietropoli Alberto , Weber Matthias

Recombinant human growth hormone (GH) is not indicated for use during pregnancy and in women of childbearing potential not using contraception. Nonetheless, in clinical practice, some women taking GH replacement conceive during treatment and many continue GH during their pregnancy. Here we report data on GH-treated women enrolled in two complementary, international, non-interventional registry studies, NordiNet IOS (NCT00960128; 2006–2016) and ANSWER (NCT01009905; 2002&#...